A combination vaccine for COVID and influenza is showing promising results in phase 3 trials conducted by Moderna. The experimental vaccine, mRNA-1083, has demonstrated a better immune response compared to other vaccines currently available. This vaccine combines Moderna’s candidate for seasonal influenza (mRNA-1010) with their next-generation COVID-19 vaccine candidate (mRNA-1283).
According to Francesca Ceddia, the chief medical affairs officer at Moderna, this development marks a significant milestone in the quest for a dual vaccine that could revolutionize the management of respiratory illnesses. The hope is that by offering dual protection in a single shot, along with enhanced immunity, compliance and public health outcomes can be improved.
Moderna’s phase 3 trial involved two groups of 4,000 adults each, including individuals aged 65 and older as well as those between 50 and 64. The results showed statistically significantly higher immune responses against three strains of influenza virus and SARS-CoV-2. The vaccine’s safety profile was deemed acceptable, with common adverse reactions being mild and temporary.
Experts like Dr. Joseph A. Ladapo and Dr. Marc Siegel have shared their perspectives on the vaccine. While some concerns have been raised about the safety of mRNA vaccines, the overall efficacy and benefits of the COVID-flu combination vaccine are widely recognized. The convenience of a single shot that offers protection against both viruses could potentially boost vaccination rates, particularly among older adults who are at higher risk.
Looking ahead, Moderna plans to present the phase 3 clinical data at a medical conference and submit it for publication. Other pharmaceutical companies like Novavax and Pfizer-BioNTech are also working on similar combination vaccines, highlighting the growing interest in this approach to disease prevention.
As vaccination rates for both COVID and influenza remain below optimal levels in the United States, the development of a dual vaccine could be a game-changer in public health efforts. By streamlining the vaccination process and improving overall immunity, this new vaccine has the potential to make a significant impact in combating respiratory illnesses and reducing severe outcomes associated with both COVID-19 and the flu.